ArticleCancers2023

Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas.

Angela Buonadonna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.